InteRNA CEO on cancer monotherapy ambition for lead drug

Roel Schaapveld, CEO of InteRNA, chats with Scrip on the sidelines of the 2018 BIO-Europe partnering event about upcoming milestones for the company's RNA pipeline. The Dutch company expects to study and eventually file its lead compound as a monotherapy treatment for hepatocellular carcinoma. Schaapveld believes the drug can show efficacy outside of combination regimens.